Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Opioid-Induced Constipation - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
The report covers comprehensive insights of present clinical development scenario and growth prospects across the Opioid-Induced Constipation market. A detailed picture of the Opioid-Induced Constipation pipeline landscape is provided, which includes the disease overview and Opioid-Induced Constipation treatment guidelines. The assessment part of the report embraces in-depth Opioid-Induced Constipation commercial assessment and clinical assessment of the Opioid-Induced Constipation pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid-Induced Constipation collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Opioid-Induced Constipation with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Opioid-Induced Constipation treatment.
- Opioid-Induced Constipation key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Opioid-Induced Constipation market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
In-depth Opioid-Induced Constipation Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Opioid-Induced Constipation Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Scope of the Report
- The Opioid-Induced Constipation report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Opioid-Induced Constipation across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Opioid-Induced Constipation therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Opioid-Induced Constipation research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Opioid-Induced Constipation.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Opioid-Induced Constipation.
- In the coming years, the Opioid-Induced Constipation market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Opioid-Induced Constipation R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Opioid-Induced Constipation treatment market. Several potential therapies for Opioid-Induced Constipation are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Opioid-Induced Constipation market size in the coming years.
- This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Opioid-Induced Constipation) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
- What are the current options for Opioid-Induced Constipation treatment?
- How many companies are developing therapies for the treatment of Opioid-Induced Constipation?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Opioid-Induced Constipation?
- How many Opioid-Induced Constipation emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Opioid-Induced Constipation?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Opioid-Induced Constipation market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Opioid-Induced Constipation?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Opioid-Induced Constipation therapies?
- What are the clinical studies going on for Opioid-Induced Constipation and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Opioid-Induced Constipation?
- How many patents are granted and pending for the emerging therapies for the treatment of Opioid-Induced Constipation?
Key Topics Covered:
1. Report Introduction
2. Opioid-Induced Constipation
2.1. Overview
2.2. History
2.3. Opioid-Induced Constipation Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. Opioid-Induced Constipation Diagnosis
3. Opioid-Induced Constipation Current Treatment Patterns
3.1. Opioid-Induced Constipation Treatment Guidelines
4. Opioid-Induced Constipation - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Opioid-Induced Constipation companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Opioid-Induced Constipation Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Opioid-Induced Constipation Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.3. Assessment by Route of Administration
5.1.4. Assessment by Molecule Type
5.1.5. Assessment by MOA
5.1.6. Assessment by Target
6. Opioid-Induced Constipation Late Stage Products (Phase-III)
7. Opioid-Induced Constipation Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Opioid-Induced Constipation Discontinued Products
13. Opioid-Induced Constipation Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report
14. Opioid-Induced Constipation Key Companies
15. Opioid-Induced Constipation Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Opioid-Induced Constipation Unmet Needs
18. Opioid-Induced Constipation Future Perspectives
19. Opioid-Induced Constipation Analyst Review
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/chqlql
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
